ACE Inhibitors Show Significant Mortality Reduction in Idiopathic Pulmonary Fibrosis Patients
Key Insights
A retrospective study of 7,158 patients found that ACE inhibitor use within 5 years before IPF diagnosis was independently associated with an 18% reduction in all-cause mortality risk.
The survival benefit was specific to IPF patients, with no significant mortality reduction observed in matched COPD patients, suggesting disease-specific mechanisms.
Researchers analyzed data from 3,579 IPF patients matched with 3,579 COPD patients, finding 37% of IPF patients had qualifying ACE inhibitor prescriptions.
A large retrospective study has revealed that angiotensin-converting enzyme (search) (ACE) inhibitors may offer significant survival benefits for patients with idiopathic pulmonary fibrosis (search) (IPF), a progressive lung disease with limited therapeutic options and poor prognosis. The research, published in CHEST, analyzed data from 7,158 patients and found an 18% reduction in all-cause mortality risk among IPF patients who used ACE inhibitors (search).
Study Design and Patient Population
Researchers led by Burcu Ozaltin, PhD, from University College London, conducted a retrospective analysis using electronic health records from the Clinical Practice Research Datalink (search) GP Online Database. The study included 3,579 patients with IPF matched 1:1 with 3,579 patients with chronic obstructive pulmonary disease (search) (COPD) for comparison purposes.
The patient population had a mean age of 74 years, with 36% being women. Propensity score matching factored in age, sex, and smoking history to ensure comparable groups. Among the IPF cohort, 1,328 patients (37%) had three or more ACE inhibitor prescriptions within the 5 years before diagnosis, compared to 1,061 patients (30%) in the COPD group.
Significant Mortality Reduction in IPF
The study's primary finding demonstrated a substantial survival advantage for IPF patients using ACE inhibitors (search). In multivariable Cox regression analysis adjusted for multiple factors including age, sex, BMI, smoking status, diabetes mellitus (search), chronic kidney disease (search), and cardiovascular comorbidities, ACE inhibitor use was associated with significantly lower all-cause mortality risk (HR = 0.82; 95% CI, 0.75-0.91).
Notably, a similar proportion of IPF patients using and not using ACE inhibitors (search) died during the study period (both 84%), but the timing and risk factors differed significantly. A sensitivity analysis that eliminated the study's 60-day post-diagnosis exclusion criteria continued to show significantly lower mortality risk with ACE inhibitor use (HR = 0.87; 95% CI, 0.8-0.94).
Disease-Specific Benefits
The mortality benefit appeared to be specific to IPF, as researchers observed no significant association between ACE inhibitor use and all-cause mortality in the matched COPD cohort. In the COPD group, 717 patients (20%) in the ACE inhibitor users group died compared to 1,692 (47%) in the non-users group, but multivariable analysis showed no significant effect on mortality (HR = 1.09; 95% CI, 0.96-1.23; P = .180).
"We found no evidence of a mortality benefit associated with ACE inhibitor use in the matched COPD cohort, indicating that the survival advantage observed in IPF is unlikely to be explained by general cardiovascular effects alone," the researchers wrote. "This distinction suggests that the survival benefit observed in IPF may be uniquely linked to IPF-specific mechanisms, indicating a potential disease-specific effect of ACE inhibitors (search)."
Mortality Patterns and Causes
Analysis of mortality causes revealed that among IPF patients using ACE inhibitors (search), 45% of deaths were respiratory-related and 18% were cardiovascular-related. In comparison, non-users experienced 48% respiratory-related deaths and 11% cardiovascular-related deaths. However, when accounting for all competing causes of death, ACE inhibitors were not significantly associated with a reduction in respiratory-related mortality specifically.
Additional Risk Factors
The study identified several other significant factors affecting mortality risk in IPF patients. Women with IPF showed significantly decreased risk for all-cause mortality (HR = 0.68; 95% CI, 0.62-0.75), while increasing age (HR = 1.03; 95% CI, 1.02-1.04) and current smoking status (HR = 1.24; 95% CI, 1.08-1.42) significantly heightened mortality risk.
Clinical Implications and Future Directions
IPF typically affects patients over 50 years of age, predominantly males, with a median survival time of 3 to 5 years after diagnosis. The disease often presents with common cardiovascular comorbidities including arterial hypertension (search) and congestive heart failure (search), conditions for which ACE inhibitors (search) are already established treatments.
The researchers emphasized the potential value of repurposing well-established medications for new therapeutic roles in progressive diseases like IPF, where current treatment options remain limited. "These findings highlight the value of investigating well-established medications for new therapeutic roles in progressive diseases such as IPF, in which current treatment options are limited," the study authors concluded.
Study Limitations and Next Steps
The retrospective observational design limits causal inference, and residual confounding may persist despite propensity score matching. IPF diagnoses were based on electronic health record codes, which could introduce miscoding, though survival rates suggest minimal impact on the findings.
The researchers called for prospective clinical trials to validate these findings and formally explore ACE inhibitors (search) as a therapeutic option in IPF. "We encourage the design and execution of prospective trials to validate these findings and explore ACE inhibitors as a therapeutic option in IPF," they wrote.